[Evaluation of the efficiency of various treatment regimens for patients with newly-detected sarcoidosis in the Republic of Tatarstan].
The natural history of sarcoidosis was analyzed in 279 patients with its history of as long as 2 years among the 832 with this disease registered in the Republic of Tatarstan in 1999 to 2002. The patients were divided into 3 groups: (1) 79 (28.3%) receiving systemic glucocorticosteroids (SGS); (2) 146 (52.3%) patients having therapy without SGS; (3) 54 (19.3%) patients receiving no drug therapy, but they were followed up by a physician. There was no strong evidence for that it was expedient to use prednisolone in most of patients. Prednisolone exerted a significant effect on clinical manifestations, laboratory values, and radiation pattern in patients with sarcoidosis, but more commonly (28.9%) led to its relapses than alternative treatment and active follow-up. Patients treated with prednisolone and other drugs and those untreated showed no significant differences in the frequency of cases of a worse X-ray pattern during 28 years. It is advisable to follow an active observation policy in patients having a stable course of sarcoidosis, by restricting indications for the use of prednisolone in those who have apparently progressive or threatening extrapulmonary manifestations of the disease (heart, nervous system, eyes).
Vizel'
A A
AA
Nasretdinova
G R
GR
Islamova
L V
LV
Vizel'
E A
EA
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002391:Catchment Area, Health; D005260:Female; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use*; D011859:Radiography; D012426:Russia / Q000453:epidemiology; D017565:Sarcoidosis, Pulmonary / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D011241:Prednisone